» Articles » PMID: 22207738

Thermodynamic and Structural Description of Allosterically Regulated VEGFR-2 Dimerization

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2011 Dec 31
PMID 22207738
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

VEGFs activate 3 receptor tyrosine kinases, VEGFR-1, VEGFR-2, and VEGFR-3, promoting angiogenic and lymphangiogenic signaling. The extracellular receptor domain (ECD) consists of 7 Ig-homology domains; domains 2 and 3 (D23) represent the ligand-binding domain, whereas the function of D4-7 is unclear. Ligand binding promotes receptor dimerization and instigates transmembrane signaling and receptor kinase activation. In the present study, isothermal titration calorimetry showed that the Gibbs free energy of VEGF-A, VEGF-C, or VEGF-E binding to D23 or the full-length ECD of VEGFR-2 is dominated by favorable entropic contribution with enthalpic penalty. The free energy of VEGF binding to the ECD is 1.0-1.7 kcal/mol less favorable than for binding to D23. A model of the VEGF-E/VEGFR-2 ECD complex derived from small-angle scattering data provided evidence for homotypic interactions in D4-7. We also solved the crystal structures of complexes between VEGF-A or VEGF-E with D23, which revealed comparable binding surfaces and similar interactions between the ligands and the receptor, but showed variation in D23 twist angles. The energetically unfavorable homotypic interactions in D4-7 may be required for re-orientation of receptor monomers, and this mechanism might prevent ligand-independent activation of VEGFR-2 to evade the deleterious consequences for blood and lymph vessel homeostasis arising from inappropriate receptor activation.

Citing Articles

Nonclinical Similarity of the Biosimilar Candidate ABP 938 with Aflibercept Reference Product.

Seo N, Kuhns S, Andrews D, Colbert A, Chow V, Liu J Ophthalmol Ther. 2024; 14(1):85-101.

PMID: 39503991 PMC: 11724829. DOI: 10.1007/s40123-024-01043-5.


An Ensemble Docking Approach for Analyzing and Designing Aptamer Heterodimers Targeting VEGF.

Go Y, Kalathingal M, Rhee Y Int J Mol Sci. 2024; 25(7).

PMID: 38612876 PMC: 11012306. DOI: 10.3390/ijms25074066.


Analytical and Functional Similarity of Aflibercept Biosimilar ABP 938 with Aflibercept Reference Product.

Seo N, Guan X, Wang T, Chung H, Wikstrom M, Padaki R Ophthalmol Ther. 2024; 13(5):1303-1320.

PMID: 38507189 PMC: 11039433. DOI: 10.1007/s40123-024-00914-1.


Differential antiangiogenic and anticancer activities of the active metabolites of ginsenoside Rg3.

Nakhjavani M, Smith E, Yeo K, Tomita Y, Price T, Yool A J Ginseng Res. 2024; 48(2):171-180.

PMID: 38465222 PMC: 10920002. DOI: 10.1016/j.jgr.2021.05.008.


NRP1 interacts with endoglin and VEGFR2 to modulate VEGF signaling and endothelial cell sprouting.

Sharma S, Ehrlich M, Zhang M, Blobe G, Henis Y Commun Biol. 2024; 7(1):112.

PMID: 38242992 PMC: 10799020. DOI: 10.1038/s42003-024-05798-2.